John Craighead, Ph.D.
About John Craighead, Ph.D.
John Craighead, Ph.D., serves as the Chief Operating Officer and Chief Financial Officer at HALO Precision Diagnostics, bringing over 20 years of experience in biotechnology and financial services to the role. He has held various leadership positions in notable companies, including GRAIL, Sanofi, and Elpiscience Biopharmaceuticals.
Work at HALO Diagnostics
John Craighead, Ph.D., serves as the Chief Operating Officer and Chief Financial Officer at HALO Precision Diagnostics. He has held this position since 2023, contributing to the company's operations and financial strategies. His role involves overseeing various aspects of the organization, ensuring efficient management and alignment with corporate objectives. HALO Precision Diagnostics focuses on precision diagnostics, and Craighead's leadership is integral to its mission.
Previous Experience in Biotechnology
Prior to his current role, John Craighead held several significant positions in the biotechnology sector. He worked as Chief Financial Officer and Head of Corporate Development at Elpiscience Biopharmaceuticals, Inc. for eight months in 2022. He also served as Vice President of Strategy, Corporate Development & Investor Relations at GRAIL, Inc. in 2021. His extensive experience includes roles at Human Genome Sciences, Atara Biotherapeutics, and Sanofi, where he focused on investor relations and corporate development.
Education and Expertise
John Craighead holds a Bachelor of Arts in Chemistry and Molecular Biology from St. Olaf College, where he was awarded the Barry M. Goldwater Scholarship. He furthered his education at Scripps Research, earning a Doctor of Philosophy (Ph.D.) in Cell Biology. His academic background supports his expertise in biotechnology, eukaryotic transcription regulation, and clinical development economics, evidenced by numerous academic publications.
Career in Financial Services
In addition to his biotechnology experience, John Craighead has a background in financial services. He worked as a Biotechnology Analyst at Lehman Brothers from 2004 to 2007. His career also includes roles at the Biotechnology Industry Organization, where he served as Managing Director of Investor Relations and Business Development. This combination of biotechnology and financial expertise positions him uniquely in his current leadership roles.
Achievements and Recognitions
John Craighead has received notable recognitions throughout his career, including the National Science Foundation Fellowship. He has contributed to the academic community through numerous publications in the fields of eukaryotic transcription regulation and clinical development economics. His extensive experience in both biotechnology and finance, spanning over 20 years, underscores his contributions to the industry.